Copyright© KANEHARA & Co., LTD. All Rights Reserved.
| Classification of Lung Cancer | |
|---|---|
 |
1st English ed., 2000 sizes : 257 x 182mm ORDER(amazon.co.jp) |
Preface
The Japan Lung Cancer Society was organized in 1955, and today, with more than 8,000 members and various committees, it plays an important role in the field of lung cancer in Japan. The goals of the Japan Lung Cancer Society are to contribute to the improvement of continuing study and treatment of lung cancer, and promote practical training in diagnosis and treatment for lung cancer patients.
In particular, the establishment of common rules for pathological and clinical descriptions is essential. In 1978, the first Japanese edition of the General Rules for Clinical and Pathological Recording of Lung Cancer was published, as a systematic practical and theoretical guideline. According to these rules, surgical results were registered, statistically analyzed, and entered into a database. The common rules enable comparison and study of surgical and nonsurgical results in different hospitals and institutes, and should result in patient benefits. The General Rules have undergone several revisions, and currently the 5th edition is used extensively.
Internationally, for lung cancer, the International Union Against Cancer (UICC) has established the TNM staging, and the World Health Organization (WHO) also establishes the histological typing. The International Association for the Study of Lung Cancer (IASLC) has a staging committee devoted to categories and factors, such as TNM categories, of the stage grouping.
Here, we present the first English edition of the Classification of Lung Cancer of the Japan Lung Cancer Society, with illustrations and detailed descriptions. This English edition is based on the Japanese version of the General Rules.
This manual is composed of seven parts: anatomy, preoperative findings, surgical findings, nonsurgical findings, histological findings, cytological findings, and mass screening.
I sincerely hope that this English edition will be widely accepted, and that it will contribute to treatment of lung cancer, which will in turn contribute to the treatment of common international criteria.
March 2000
Harubumi KATO, MD, PhD
Chairman,
English Edition Subcommitte